Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Oric Pharmaceuticals Inc. | ORIC-533 and elranatamab | Multiple myeloma | Phase 2 | Enrollment Conclusion | ORIC-533 oral elranatamab subcutaneous | Oncology |
| Oruka Therapeutics Inc. | Gencaro - (PRECISION-AF) | Chronic Heart Failure | Phase 3 | Trial Discontinued | Oral | Cardiology |
| Oruka Therapeutics Inc. | rNAPc2 (AB201) - (ASPEN) | COVID-19 | Phase 2b | Trial Completed | Intravenous | COVID-19 |
| Oruka Therapeutics Inc. | ORKA-001 - (EVERLAST-B) | Plaque psoriasis | Phase 2 | Ongoing | oral | Immunology: Anti-TNF |
| Oruka Therapeutics Inc. | ORKA-001 - (EVERLAST-A) | Moderate-to-severe plaque psoriasis | Phase 2a | Trial Planned | Oral | Immunology: Anti-TNF |
| OS Therapies Incorporated | OST-HER2 (AOST-2121) | Resected osteosarcoma | BLA Filing | Data Released | Intravenous | Oncology |
| Outlook Therapeutics Inc. | ONS-5010 - (NORSE 3 open-label) | Wet age-related macular degeneration (wet AMD) | BLA Filing | Ongoing | Intravitreal | Opthalmic |
| Outlook Therapeutics Inc. | ONS-5010-001 - (NORSE 1) | Wet age-related macular degeneration (wet AMD) | BLA Filing | Ongoing | Intravitreal | Opthalmic |
